Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCl, in metastatic breast cancer

Journal of Clinical Oncology

Volumn 19, Issue 7, 2001, Pages 2002-2009

  Munster P N ^a   Buzdar, A ^a   Dhingra, K ^a   Enas, N ^a   Ni, L ^a   Major, M ^a   Melemed, A ^a   Seidman, A ^a   Booser, D ^a   Theriault, R ^a   Norton, L ^a   Hudis, C ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARZOXIFENE; BENZOTHIOPHENE DERIVATIVE; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HOT FLUSH; HUMAN; METASTASIS; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0035299504     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.7.2002     Document Type: Article

References (30)

1. Cancer statistics, 1999
2. On the treatment of inoperable cases of carcinomas of the mamma: Suggestions for a new method of treatment, with illustrative cases
3. The effect of tamoxifen on the endometrium
4. Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin III levels
5. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women
6. Tamoxifen in advanced breast cancer
7. Tamoxifen. Use in treatment of metastatic breast cancer refractory to combination chemotherapy
8. Tamoxifen as initial endocrine therapy for metastatic breast cancer: Long term follow-up of two Piedmont Oncology Association (POA) trials
9. Acquired tamoxifen resistance in human breast cancer: Potential mechanisms and clinical implications
10. Mechanisms of tamoxifen resistance
11. Comparative pharmacology of high potency selective estrogen receptor modulators (SERMs): LY353381.HCl and CP336,156
12. The new SERM LY353381oHCl has advantages over estrogen, tamoxifen, and raloxifene in reproductive and nonreproductive tissues of aged ovariectomized rats
13. The disposition and biotransformation of the selective estrogen receptor for modulator, LY353381, in female Fischer 344 rats following a single oral dose
14. 14C-LY353381
15. LY353381.HCl: A novel raloxifene analog with improved SERM potency and efficacy in vivo
16. Preclinical demonstration of specific and potent inhibition of mammary tumor growth by new selective estrogen receptor modulators (SERMs)
17. LY353381 x HCl: An improved benzothiophene analog with bone efficacy complementary to parathyroid hormone-(1-34)
18. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen
19. Peptide antagonists of the human estrogen receptor
20. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
21. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial -Multiple Outcomes of Raloxifene Evaluation
22. Long term dosing of LY353381.HCl preserves bone quality, reduces turnover and lowers cholesterol levels in ovariectomized rats
23. Thrombosis with low-estrogen oral contraceptives
24. Venous thrombosis as a side effect of tamoxifen treatment
25. Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women
26. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer
27. Sex hormones in postmenopausal women with breast cancer on tamoxifen
28. Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients
29. Pharmacokinetics of LY353381 in healthy postmenopausal women after multiple dose oral administration
30. Double-blind randomized phase II study of a selective estrogen receptor modulator in patients with locally advanced or metastatic breast cancer